A large trial of ranibizumab (Lucentis, Novartis) for wet age-related macular degeneration (AMD) has shown no new safety signals.Patients received an average of 4 to 6 injections over 12 months and had a visual acuity gain of 7 letters.The first of 4 planned yearly updates of the ongoing LUMINOUS trial were presented here at the 12th EURETINA Congress; it is expected that the final results will be published in 2016.The trial is assessing the safety, efficacy, and treatment patterns across countries of ranibizumab.The retrospective phase of the study involved pooled data from nearly 4500 patients with wet AMD from 4 European registries treated with ranibizumab in routine clinical practice, outside of clinical trials.To see more details visit,www.medscape.com